Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805067 | 1.00 | TDP1 (0.47) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL28909298 | 0.83 | TDP1 (0.45) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL30627320 | 0.82 | ALDH1A1 (0.50) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL1999849 | 0.82 | ALDH1A1 (0.50) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL3010961 | 0.81 | TDP1 (0.61) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL1459395 | 0.81 | TSHR (0.53) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL1995565 | 0.81 | TDP1 (0.47) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL9747305 | 0.79 | TDP1 (0.67) | TDP1ALDH1A1GPR35SMN1; SMN2HSD17B10 | |
| SCHEMBL9175349 | 0.79 | TDP1 (0.50) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 | |
| SCHEMBL7775267 | 0.79 | ALDH1A1 (0.46) | TDP1ALDH1A1GPR35TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115141100-B | Preparation method of 2-fluoro-3-trifluoromethyl aniline | 苏州永健生物医药有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-115141100-A | Preparation method of 2-fluoro-3-trifluoromethylaniline | 苏州永健生物医药有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-122079945-A | Coumarin derivative containing substituted phenyl ether structure, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-31 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-120136707-A | Preparation method of 3-bromo-4-fluoro-5-trifluoromethylaniline | 杭州国瑞生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2005063254-A2 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4172831-A | CENTRAL NERVOUS SYSTEM | LILLY INDUSTRIES LIMITED (GB) | 1979-10-30 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4115574-A | CNS ACTIVITY | LILLY INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
| US-4115568-A | CNS ACTIVITY | LILLY INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | TDP1 2748/4885ALDH1A1 2038/4885GPR35 4575/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | TDP1 798/4885ALDH1A1 2427/4885GPR35 4559/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | TDP1 1543/4885ALDH1A1 1201/4885GPR35 3464/4885 |
| US-12590086-B2 | 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression | GPR139, OPRL1, GRIN2C | TDP1 1593/4885ALDH1A1 1460/4885GPR35 50/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | TDP1 798/4885ALDH1A1 2427/4885GPR35 4559/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | TDP1 223/4885ALDH1A1 1483/4885GPR35 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.